Aim: it has been reported that metastasis-associated lung adenocarcinoma transcript 1 is abnormally expressed in various cancers.
Methods: eligible studies fulfilling the search criteria were selected from the online databases. Statistical analysis was performed based on the platforms of STATA 14.0.
Results: 12 studies were included in this study comprising 741 cases and 794 controls. The pooled results were shown as follows: sensitivity, 0.74 (95% CI: 0.64-0.82), specificity, 0.83 (95% CI: 0.75-0.88), positive likelihood ratio (PLR), 4.2 (95% CI: 3.00-5.90), negative likelihood, 0.32 (95% CI: 0.23-0.43), diagnostic odds ratio, 13 (95%CI: 8.00-21.00) and area under the curve, 0.85 (95%CI: 0.82-0.88). Deeks' funnel plot asymmetry test (p = 0.70) suggested no potential publication bias.
Conclusion: long noncoding RNA Metastasis-associated lung adenocarcinoma transcript 1 might be a usable biomarker for cancer diagnosis and detection.
Keywords: cancer; diagnosis; long noncoding RNA MALAT1; meta-analysis; prognosis.